AMLX

#2013
Amylyx Pharmaceuticals, Inc. Common Stock
16.92 USD
+2.73%
부문: 헬스케어
베이스: USD
수익 통화: USD
일일 변동 비율
16.92
16.92
년간 변동
3.79
17.49
일일 변동
+2.73%
월간 변동
+19.24%
6달 변화
+15.89%
년간 변동율
+332.74%
이전 종가
16.47
Open
16.92
Bid
Ask
Low
16.92
High
16.92
양
87
Open full chart

Financials

Overview 성명 Statistics Dividends
Quarterly Annual
Income statement Balance sheet Cash flow
Value 2022202320242025 TTM

Amylyx Pharmaceuticals Inc

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024.

뉴스